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We previously reported that the ApoE e4e4 genotype was associated 
with COVID-19 test positivity (odds ratio [OR]  =  2.31, 95% CI: 
1.65–3.24, p = 1.19 × 10−6) (1) in the UK Biobank (UKB) cohort, 
during the epidemic peak in England, from March 16 to April 26, 
2020 (2). With more COVID-19 test results (March 16 to May 31, 
2020) and mortality data (to March 31, 2020, with incomplete data 
for April 2020)  linked to UKB, we reevaluated the ApoE e4 allele 
association with COVID-19 test positivity, and with all-cause mor-
tality following test-confirmed COVID-19.
We restricted analyses to European-ancestry participants (3) 
(n = 451 367, 90% of sample) attending baseline assessment cen-
ters in England (n = 398 073) and excluded participants who died 
before the pandemic (set at February 1, 2020, n = 22 384). Single-
nucleotide polymorphism data for rs429358 and rs7412 were used 
to determine ApoE genotypes. Our outcomes of interest were: (a) 
COVID-19 test positive versus the rest of the sample meeting inclu-
sion criteria (ie, including untested samples and tested negative), and 
(b) tested positive and died versus the rest of the sample as above, 
but with additional exclusion of test positive participants who sur-
vived. Some of the excluded samples could have died but cannot be 
identified due to incomplete mortality data for April 2020. Logistic 
regression models compared ApoE e4e4 participants (or e3e4s) to 
e3e3s with adjustment for sex; age on April 26 or age at death; base-
line UKB assessment center in England (accounting for geographical 
differences in viral exposures); genotyping array type; and the top 
five genetic principal components (accounting for possible popula-
tion admixture).
The mean attained age was 68.2 years (SD = 8.0) with 174 667 
females (55%). Of 219  747 e3e3 participants, 663 participants 
tested positive (302 per 100 000), of whom, 79 later died. Similarly, 
of 8767 e4e4 participants, 59 tested positive (673 per 100 000), 
of whom 13 later died (Table 1). In logistic models, ApoE e4e4 
genotype was associated with increased risks of test positivity 
(OR = 2.24, 95% CI: 1.72–2.93, p = 3.24 × 10−9) and of mortality 
with test-confirmed COVID-19 (OR = 4.29, 95% CI: 2.38–7.72, 
p = 1.22 × 10−6), compared to e3e3s. For e3e4s versus e3e3s, these 
two associations were nominally statistically significant (at p < 
.05), but with much smaller effect sizes. The e4e4 associations 
were similar after excluding 50  566 participants related to the 
third degree or closer for test positivity (e4e4 OR = 2.30, 95% CI: 
1.73–3.07, p = 1.39 × 10−8) and for mortality with test-confirmed 
COVID-19 (e4e4 OR = 4.53, 95% CI: 2.39–8.61, p = 3.87 × 10−6). 
Additionally, the e4e4 association with either COVID-19 out-
come was little changed after removing participants with diseases 
associated with ApoE e4 alleles (4) and COVID-19 severity (5), 
including dementia, hypertension, coronary artery disease (myo-
cardial infarction or angina), or type 2 diabetes (Table 1), based 
on diagnoses recorded from baseline self-reports and hospital dis-
charge records during follow-up to March 2017. ApoE e3e4s were 
modestly associated with test positivity overall, and the associ-
ation tended to be less marked in disease-free samples (Table 1). In 
additional analyses, we tested associations with ApoE e2 alleles, 
which have been linked to beneficial health outcomes (4). No as-
sociations were found between e2e3 and either of our COVID-19 
outcomes (p > .05, vs e3e3). Analyses for e2e2s associations were 
underpowered (n = 2427, 4 positives, and 1 positive death).
The results presented imply a recessive effect of the ApoE e4 al-
lele. Only modest associations were present between the much more 
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common e3e4 genotype and COVID-19 outcomes, similar to re-
sults for rs429358 (which separates 0, 1, and 2 copies of e4 alleles, 
OR = 1.3, p = .0026) reported for severe COVID-19 with respiratory 
failure in a recent additive effect genome-wide analysis (6). ApoE e4e4 
associations with test positivity and mortality were little affected by 
excluding dementia and other ApoE e4-associated diagnoses reported 
before March 2017: future work should include recent preexisting 
diagnoses. More data are needed on ApoE and COVID-19 associ-
ations in other ancestry groups, as numbers of UKB participants of 
such groups are unfortunately too small for this analysis.
In conclusion, ApoE e4e4 genotype is associated with COVID-
19 test positivity at genome-wide significance (ie, p < 5 × 10−8) in 
UKB, using data covering a longer period than previously reported. 
Similarly, the e4e4 genotype was associated with a 4-fold increase in 
mortality after testing positive for COVID-19, in UKB. Independent 
replications are needed to confirm our findings and mechanistic 
work is needed to understand how ApoE e4e4 results in the marked 
increase in vulnerability, especially for COVID-19 mortality. These 
findings also demonstrate that risks for COVID-19 mortality are not 
simply related to advanced chronological age or the comorbidities 
commonly seen in aging.
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